Pds biotech announces pds0202 elicits active neutralization of multiple influenza strains in preclinical studies

Princeton, n.j., sept. 20, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced its investigational universal influenza vaccine pds0202 demonstrated active neutralization across multiple influenza viruses. the vaccine also provided protection against infection after challenged with high doses of the h1n1 virus in ferrets not previously exposed to flu. the data were presented in an oral lecture at the 9th european scientific working group on influenza (eswi) conference in valencia, spain by james allen, phd, from the cleveland clinic laboratory of renowned influenza expert, ted ross, phd.
PDSB Ratings Summary
PDSB Quant Ranking